HLA-A and neoplasm: Collectively, our data suggested that ePAC, as tumor vaccine, can elicit antigen-specific immune responses in humanized mice with HLA-A*0201 restriction, highlighting its potential as an effective immunotherapeutic strategy for activating the human immune system to induce potent antitumor immunity.